[go: up one dir, main page]

MXPA99001870A - Antagonistas del receptor de taquicinina,no peptidicos. - Google Patents

Antagonistas del receptor de taquicinina,no peptidicos.

Info

Publication number
MXPA99001870A
MXPA99001870A MXPA99001870A MX9901870A MXPA99001870A MX PA99001870 A MXPA99001870 A MX PA99001870A MX PA99001870 A MXPA99001870 A MX PA99001870A MX 9901870 A MX9901870 A MX 9901870A MX PA99001870 A MXPA99001870 A MX PA99001870A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
tachykinin receptor
peptide tachykinin
compounds
peptide
Prior art date
Application number
MXPA99001870A
Other languages
English (en)
Inventor
Henry Walker Lunn William
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA99001870A publication Critical patent/MXPA99001870A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invencion se relaciona con los metodos para el tratamiento o prevencion de un padecimiento fisiologico asociado con un exceso de taquicininas, el cual metodo comprende administrar a un mamifero que necesita de tal tratamiento una cantidad efectiva de un compuesto de Formula I (Ver Formula) en donde: A es -0-, -S(O)m-, N(R11)-, -CH2CH2-1 0 -CH=CH-; m es 0, 1, o 2; X es un enlace o un alquilidenilo de C1-C4; R2 es un grupo de formula (Ver Formula) en donde R y R son independientemente alquilo de C1-C6, o se combinan para formar, junto con el nitrogeno al cual se encuentran unidos, un anillo heterociclico seleccionado del grupo que consiste de hexametileniminilo, piperacino, heptametileniminilo, 4-metilpiperidinilo, imidazolinilo, piperidinilo, pirrolidinilo, o morfolinilo; R es hidroxi, halo, hidrogeno, cicloalquilo de C3-C8, alcanoiloxi de C2-C7, alcoxi de C1-C6, o fenilo, el fenilo esta opcionalmente sustituido con uno, dos, o tres porciones seleccionadas del grupo que consiste de alquilo de C1-C4, alcoxi de C1-C4, nitro, cloro, fluor, trifluorometil-OSO2-(alquilo de C1-C10) (Ver Formula) R1 es hidroxi, halo, hidrogeno, cicloalquilo de C3-C8, alcanoiloxi de C2-C7, alcoxi de C1-C6, o fenilo, el fenilo esta opcionalmente sustituido con uno, dos, o tres porciones seleccionadas del grupo que consiste de alquilo de C1-C4 alcoxi de C1-C4; nitro, cloro, fluor, trifluorometil -OSO2-(alquilo de C1-C10) (Ver Formula) cada R3 se selecciona independientemente de alquilo de Cl-C6 cicloalquilo de C3-C8, fenilo no sustituido o sustituido en donde el sustituyente es halo, alquilo de C1-C6 o alcoxi de Cl-C6; con la condicion de que cuando X es un enlace y A es -S-, R y, R1 son ambos seleccionados del grupo que consiste de hidroxi, metoxi, y alcanoiloxi de C2-C7; o una sal o solvato farmaceuticamente aceptable del mismo.
MXPA99001870A 1993-12-21 1999-02-25 Antagonistas del receptor de taquicinina,no peptidicos. MXPA99001870A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17113493A 1993-12-21 1993-12-21

Publications (1)

Publication Number Publication Date
MXPA99001870A true MXPA99001870A (es) 2004-09-06

Family

ID=22622667

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA99001870A MXPA99001870A (es) 1993-12-21 1999-02-25 Antagonistas del receptor de taquicinina,no peptidicos.

Country Status (7)

Country Link
EP (1) EP0736007A4 (es)
JP (1) JPH09506898A (es)
AU (1) AU1339795A (es)
CA (1) CA2176130A1 (es)
MX (1) MXPA99001870A (es)
WO (1) WO1995017382A1 (es)
ZA (1) ZA9410040B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
WO1995017095A1 (en) * 1993-12-21 1995-06-29 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
IL115613A0 (en) * 1994-10-20 1996-01-19 Lilly Co Eli Bicyclic neuropeptide y receptor antagonists
WO1996012488A1 (en) * 1994-10-20 1996-05-02 Eli Lilly And Company Bicyclic bradykinin receptor antagonists
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
PT910369E (pt) * 1996-03-26 2010-06-04 Lilly Co Eli Benzotiofenos, formulações que os contêm, e métodos
CA2206752A1 (en) 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
DE69824410T2 (de) 1997-04-30 2005-06-02 Eli Lilly And Co., Indianapolis Antithrombosemittel
JP2002514217A (ja) 1997-04-30 2002-05-14 イーライ・リリー・アンド・カンパニー 抗血栓物質
CA2287993A1 (en) 1997-04-30 1998-11-05 Mary George Johnson Antithrombotic agents
EP1027051B1 (en) 1997-04-30 2005-01-05 Eli Lilly And Company Antithrombotic agents
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
DE69904427T2 (de) * 1998-10-28 2003-07-17 Eli Lilly And Co., Indianapolis Benzothiophenderivate als antithrombotische Mitteln und Zwischenprodukte
WO2001032625A1 (en) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
ES2259376T3 (es) 2001-05-22 2006-10-01 Eli Lilly And Company 1,2,3,4-tetrahidroquinolinas 2-sustituidas y sus derivados, composiciones y procedimientos.
ES2236536T3 (es) 2001-05-22 2005-07-16 Eli Lilly And Company Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
GB0130305D0 (en) * 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
NZ565111A (en) 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2717509A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EA020553B1 (ru) 2009-05-12 2014-12-30 Олбани Молекьюлар Рисерч, Инк. 7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
CN102638981B (zh) 2009-10-14 2015-07-22 默沙东公司 提高p53活性的取代的哌啶和其用途
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
IN2013MN02170A (es) 2011-04-21 2015-06-12 Piramal Entpr Ltd
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
MA53287A (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Inhibiteurs de prmt5
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138163A (en) * 1965-05-21 1968-12-27 Bristol Myers Co Benzothiophene derivatives having anti-fertility properties
US3975537A (en) * 1973-09-21 1976-08-17 Smith Kline Pharmaceutical compositions and methods of producing coronary vasodilation
US3880891A (en) * 1973-09-21 1975-04-29 Smithkline Corp Substituted benzofurans
US3947470A (en) * 1974-06-20 1976-03-30 Smithkline Corporation Substituted benzofurans and benzothiophenes
US4024273A (en) * 1974-06-20 1977-05-17 Smithkline Corporation Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
WO1995017382A1 (en) 1995-06-29
JPH09506898A (ja) 1997-07-08
ZA9410040B (en) 1996-06-18
AU1339795A (en) 1995-07-10
EP0736007A4 (en) 1997-03-19
CA2176130A1 (en) 1995-06-29
EP0736007A1 (en) 1996-10-09

Similar Documents

Publication Publication Date Title
MXPA99001870A (es) Antagonistas del receptor de taquicinina,no peptidicos.
IL111615A0 (en) Non-peptide tachykinin receptor antagonists
ES2072096T3 (es) 4-fenilpiperidinas n-sustituidas antagonistas de opioides.
EP0766559A4 (en) CANNABINOID RECEPTOR ANTAGONISTS
YU59098A (sh) Derivati spiro-piperidina, postupak njihovog dobijanja, njihova upotreba u proizvodnji leka korisnog za lečenje ili prevenciju bolova, upalnih procesa, migrene, povraćanja i postherpetične neuralgije i farmaceutski sastav koji ih sadrži
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
NO903455L (no) Analoger av frigjoeringshormon for luteiniserende hormon samt fremstilling derav.
YU15299A (sh) Farmaceutski sastavi
AUPO755097A0 (en) Receptor agonist and antagonist
MX9805253A (es) Antagonistas del receptor de vitronectina.
GR3019782T3 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
DE69330754D1 (de) 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINE ALS NMDA REZEPTOR ANTAGONISTEN
EA199800867A1 (ru) Соединения тетрагидробетакарболина
IL128500A0 (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta (b) benzofurans
MY107354A (en) Substituted cyclohexenes as central nervous system agents
ATE282417T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
EA200100182A1 (ru) Лечение состояний тревожности
BG102229A (en) Endothelium receptor antagonists
ATE282416T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
TR200000287T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
EP0707852A3 (en) Bicyclic bradykinin receptor antagonists
EA199800204A1 (ru) Антагонисты 5-нтрецепторов для лечения дискинезии
MX9706967A (es) Indazolcarboxamidas.